Breaking News

Retrophin Appoints R&D VP

May 30, 2014

Shih oversee all medical, clinical and research functions

Alvin Shih, M.D. has been appointed executive vice president of R&D at Retrophin. Dr. Shih will oversee all medical, clinical and research functions. He joins the company from Pfizer, where he served as chief operating officer of the Rare Disease Research Unit, responsible for strategic initiatives and operational functions of the Unit.
 
Dr. Shih previously served as senior engagement manager for L.E.K. Consulting, LLC, where he provided strategic counsel on M&A transactions and growth development to life sciences companies.
 
 “I am delighted to welcome Alvin to the Retrophin team in this very important leadership position,” said Martin Shkreli, founder and chief executive officer of Retrophin. “His rare disease R&D experience and business acumen will be invaluable as we continue to advance and grow our pipeline of drugs for patients suffering from serious diseases that currently have no viable treatment options.”
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus